NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease

By  

Current Neuropharmacology, Vol. 10, Iss. 3, 2012-09 ,pp. : 272-285

Bentham Science Publishers

Access to resources Recommend Favorite

Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives

By  

Current Pharmaceutical Design, Vol. 20, Iss. 18, 2014-06 ,pp. : 3083-3092

Bentham Science Publishers

Access to resources Recommend Favorite

The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer’s disease

By Doggrell Sheila A  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 1, 2004-01 ,pp. : 69-72

Informa Healthcare

Access to resources Recommend Favorite

Plasma Metabolic Profiling of Mild Cognitive Impairment and Alzheimer's Disease Using Liquid Chromatography/Mass Spectrometry

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 14, Iss. 2, 2014-09 ,pp. : 113-120

Bentham Science Publishers

Access to resources Recommend Favorite

White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies

By Radanovic Marcia   Pereira Fabrício Ramos Silvestre   Stella Florindo   Aprahamian Ivan   Ferreira Luiz Kobuti   Forlenza Orestes Vicente   Busatto Geraldo F  

Expert Review of Neurotherapeutics, Vol. 13, Iss. 5, 2013-05 ,pp. : 483-493

Informa Healthcare

Access to resources Recommend Favorite